Kodiak Sciences Inc. Notes to Consolidated Financial Statements (in thousands, except share and per share data) 102 10. Prefer f red Stock As of December 31, 2023 and 2022, the Company’s amended and restated certific f ate of incorporation authorized the Company to issue up to 10,000,000 shares of prefer f red stock at the par value of $0.0001 per share. As of December 31, 2023, there are no shares of the Company’s prefer f red stock issued or outstanding. 11. Common Stock As of December 31, 2023 and 2022, the Company’s amended and restated certific f ate of incorporation authorized the Company to issue 490,000,000 shares of common stock at the par value of $0.0001 per share. Each share of common stock is entitled to one vote. The board of directors may declare and pay dividends to holders of common stock. The Company has never declared or paid any dividends on common stock. The Company had reserved common stock for future issuances as follows: December 31, 2023 December 31, 2022 Exercise of options outstanding and release of restricted shares 17,766,283 16,822,629 Issuance of common stock under the 2018 Equity Incentive Plan 2,460,375 1,934,606 Issuance of common stock under the 2018 Employee Share Purchase Plan 374,358 425,179 Total 20,601,016 19,182,414 12. Stock-Based Compensation 2018 Equity i Incentiv t e Plan l In August 2018, the Company adopted the 2018 Equity Incentive Plan (“2018 Plan”), which became effe f ctive on the business day prior to the effe f ctiveness of the registration statement relating to the IPO. The 2018 Plan initially reserved 4,300,000 shares of common stock for the issuance of incentive stock options ("ISOs"), nonstatutory stock options ("NSOs"), restricted stock, restricted stock units (“RSUs”), stock appreciation rights, performance units and performance shares to employees, directors and consultants of the Company. The number of shares availabl a e for issuance increases annually on the first day of each fiscal year equal to the least of (1) 4,300,000 shares, and (2) 4% of outstanding shares of common stock as of the last day of the immediately preceding year, and (3) such other amount as determined by the board of directors. The exercise price of options must be equal to at least the fair market value of the common stock on the grant date. For ISOs, the term may not exceed ten years, except in respect to any participant with more than 10% of voting power of all classes of stock, then the term may not exceed five years and the exercise price must be equal to at least 110% of the fair market value of the common stock on the grant date. Options and RSUs granted generally vest over four years. The number of shares availabl a e for issuance increased by 2,093,354 shares in 2023 and there were 2,460,375 shares availabl a e for grant under the 2018 Plan as of December 31, 2023. 2021 Long-T g er T m r Perfor f ma r nce Incentiv t e Plan l The 2021 Long-Term Perfor f mance Incentive Plan (“2021 LTPIP”) was designed to be a long-term, pay-for- performance, incentive plan that would further align the interests of management and other eligible employees with the creation of subs u tantial long-term value for the Company's stockholders. During 2021, eligible employees were provided a one-time opportunity to "opt-in" and forgo a portion of their annual equity incentive awards in exchange for a one-time grant of performance-based stock options from the 2021 LTPIP and 2018 Plan, collectively referred to as the "LTPIP Program". There were no options granted under the LTPIP Program for the year ended December 31, 2023. Shares underlying the options granted under the LTPIP Program may be earned based on the achievement of the performance-based requirement based on stock price goals and/or certain operational milestones based on approval by the U.S. Food and Drug r Administration of a Biologics License Application in respect of a first, second, and third majo a r indication and based on sales. The performance-based requirement and operational milestones were not achieved as of December 31, 2023.